The association of adjusted plasma valproic acid concentration with CYP2C9 gene polymorphism in patients with epilepsy: a systematic review and meta-analysis

Huihui Fang,Xiaojuan Wang,Kelu Hou,Ying Zhang,Shuai Shao,Guijie Zhang,Yufei Feng,Lin Huang
DOI: https://doi.org/10.21037/atm-21-1459
IF: 3.616
2021-05-01
Annals of Translational Medicine
Abstract:BACKGROUND: Valproic acid (VPA) is a common antiepileptic drug used to treat both generalized and partial epilepsy. Although there is increasing evidence to suggest that <i>CYP2C9</i> gene polymorphisms are associated with interindividual variability of VPA metabolism, the results are debatable. Therefore, in the present study, we conducted a meta-analysis to evaluate the correlation between <i>CYP2C9</i> gene polymorphisms and adjusted plasma VPA concentration.METHODS: The EMBASE, MEDLINE, and Cochrane Library databases were searched to obtain relevant studies. Eligible articles were reviewed, and data extraction was performed. We calculated 95% confidence intervals (CIs) and mean differences (MDs) to assess the strength of the relationship of <i>CYP2C9</i> gene polymorphisms with adjusted plasma VPA concentration.RESULTS: The meta-analysis included 6 studies involving 847 patients with epilepsy. The pooled analysis showed that the <i>CYP2C9</i> A1075C (AA <i>vs.</i> AC) polymorphism was related to the adjusted plasma concentration of VPA (P=0.02, I<sup>2</sup>= 82%). Additionally, the AC phenotype statistically significantly increased the adjusted plasma VPA concentration in children compared with the mixed age subgroup (P=0.04, I<sup>2</sup>= 48%). A similar association was observed between the AC phenotype for Asians (P&lt;0.00001, I<sup>2</sup>=0%) but not for Caucasians (P=0.34, I<sup>2</sup>=87%).DISCUSSION: Age might be a crucial covariate influencing the dosage-adjusted VPA concentration in patients with epilepsy. A reduced VPA dosage may be recommendable for children, particularly Asian children, who are <i>CYP2C9</i> A1075C AC carriers. Further studies could provide high-quality evidence to confirm the correlation between VPA pharmacokinetics and <i>CYP2C9</i> A1075C polymorphisms.
oncology,medicine, research & experimental
What problem does this paper attempt to address?